eli lily retatrutide ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial People lost up to 85

Description

The implications extend beyond GLP-1 drugs: any complex biologic (antibodies, cell therapies, vaccines) could be designed or produced more quickly

It differs from the modest lean-mass reduction seen during weight loss, where the body adapts to lower energy needs

Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) A study published in JAMA Ophthalmology in July 2024 indicates that patients with type 2 diabetes who are taking GLP-1 receptor agonists may be at an increased risk for developing a serious and debilitating condition known as Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Systemic injection of MOTS-c can restore the level of MOTS-c in aged mice and successfully reverse age-related skeletal muscle insulin resistance

However, several studies seem to indicate that Tregs may oppose the progression of diabetic complications by mitigating insulin resistance, atherosclerosis, and damage to target organs (as in kidney disease)